
US FDA reverses course on Regenxbio's rare-disease gene therapy, backs accelerated approval bid
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPcGZad2VPWmpRYUZtS1MxYUJZejgtNi1mdFpOYkZ5c3pnZjQ0VWxBWGxMQ043a3R5MEp2QlNOQlN0YW9DS0ZGT2F4Rk9HUURkWk1pNU9FUjBGMTdHMjlWcENybGdmUmp3d3FST0hjdVFwMEVZYzM2WHBlR2pENjVqeWV0eHFDNU12cXB5Xy0tRkpYNnRjSEZDTlRSeFFxeXJWQkZ6aGFKaWVYbDZ0dmtRc2piaDg4M1E5S19XcGtWcWF3MlY2QV9UTUh6SXpMZGM?oc=5" target="_blank">US FDA reverses course on Regenxbio's rare-disease gene therapy, backs accelerated approval bid</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

